- Home
- PGEN vs ENGN Comparison
PGEN vs ENGN Comparison
Compare PGEN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGEN
- ENGN
- Stock Information
- Founded
- PGEN 1998
- ENGN 1999
- Country
- PGEN United States
- ENGN Canada
- Employees
- PGEN N/A
- ENGN N/A
- Industry
- PGEN Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- PGEN Health Care
- ENGN
- Exchange
- PGEN Nasdaq
- ENGN Nasdaq
- Market Cap
- PGEN 292.6M
- ENGN 293.1M
- IPO Year
- PGEN N/A
- ENGN N/A
- Fundamental
- Price
- PGEN $0.80
- ENGN $8.09
- Analyst Decision
- PGEN Buy
- ENGN Strong Buy
- Analyst Count
- PGEN 5
- ENGN 8
- Target Price
- PGEN $7.00
- ENGN $30.38
- AVG Volume (30 Days)
- PGEN 930.1K
- ENGN 167.2K
- Earning Date
- PGEN 11-14-2024
- ENGN 01-27-2025
- Dividend Yield
- PGEN N/A
- ENGN N/A
- EPS Growth
- PGEN N/A
- ENGN N/A
- EPS
- PGEN N/A
- ENGN N/A
- Revenue
- PGEN $3,963,000.00
- ENGN N/A
- Revenue This Year
- PGEN N/A
- ENGN N/A
- Revenue Next Year
- PGEN $426.76
- ENGN N/A
- P/E Ratio
- PGEN N/A
- ENGN N/A
- Revenue Growth
- PGEN N/A
- ENGN N/A
- 52 Week Low
- PGEN $0.76
- ENGN $4.42
- 52 Week High
- PGEN $1.93
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- PGEN 42.83
- ENGN 46.82
- Support Level
- PGEN $0.76
- ENGN $8.00
- Resistance Level
- PGEN $0.97
- ENGN $8.89
- Average True Range (ATR)
- PGEN 0.06
- ENGN 0.60
- MACD
- PGEN -0.01
- ENGN 0.02
- Stochastic Oscillator
- PGEN 20.52
- ENGN 34.35
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.